S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Safest Option in Trades! (Ad)pixel
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
The Safest Option in Trades! (Ad)pixel
Saudi Aramco's profits already $88B as oil prices stay high
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
"Prepare for Five Years of Famine" (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Safest Option in Trades! (Ad)pixel
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
The Safest Option in Trades! (Ad)pixel
Saudi Aramco's profits already $88B as oil prices stay high
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
"Prepare for Five Years of Famine" (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Safest Option in Trades! (Ad)pixel
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
The Safest Option in Trades! (Ad)pixel
Saudi Aramco's profits already $88B as oil prices stay high
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
"Prepare for Five Years of Famine" (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Safest Option in Trades! (Ad)pixel
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
The Safest Option in Trades! (Ad)pixel
Saudi Aramco's profits already $88B as oil prices stay high
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
"Prepare for Five Years of Famine" (Ad)
NASDAQ:RETA

Reata Pharmaceuticals - RETA Stock Forecast, Price & News

$21.02
+0.06 (+0.29%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$20.76
$21.50
50-Day Range
$20.96
$36.49
52-Week Range
$20.24
$116.04
Volume
733,015 shs
Average Volume
627,780 shs
Market Capitalization
$767.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$57.57

Reata Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
173.9% Upside
$57.57 Price Target
Short Interest
Bearish
17.52% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.75
Upright™ Environmental Score
News Sentiment
0.09mentions of Reata Pharmaceuticals in the last 14 days
Based on 20 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($8.27) to ($7.94) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.22 out of 5 stars

Medical Sector

585th out of 1,135 stocks

Pharmaceutical Preparations Industry

297th out of 557 stocks

RETA stock logo

About Reata Pharmaceuticals (NASDAQ:RETA) Stock

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

Analysts Set New Price Targets

RETA has been the subject of several research reports. LADENBURG THALM/SH SH reduced their price objective on Reata Pharmaceuticals from $75.00 to $67.00 in a report on Wednesday, May 11th. Robert W. Baird dropped their price target on Reata Pharmaceuticals from $37.00 to $27.00 and set a "neutral" rating for the company in a research report on Tuesday, August 9th. Citigroup raised their price target on Reata Pharmaceuticals from $43.00 to $46.00 and gave the stock a "buy" rating in a research report on Friday, May 27th. Finally, The Goldman Sachs Group dropped their price target on Reata Pharmaceuticals from $93.00 to $73.00 and set a "buy" rating for the company in a research report on Tuesday, May 24th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Reata Pharmaceuticals has a consensus rating of "Hold" and an average price target of $57.57.

Reata Pharmaceuticals Price Performance

Shares of NASDAQ:RETA traded up $0.06 during midday trading on Friday, reaching $21.02. The company's stock had a trading volume of 733,015 shares, compared to its average volume of 627,780. Reata Pharmaceuticals has a 1 year low of $20.24 and a 1 year high of $116.04. The business has a 50 day moving average price of $31.65 and a 200 day moving average price of $30.40.

Reata Pharmaceuticals (NASDAQ:RETA - Get Rating) last posted its quarterly earnings results on Monday, August 8th. The company reported ($2.02) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.90) by ($0.12). Reata Pharmaceuticals had a negative net margin of 3,045.98% and a negative return on equity of 190.87%. The firm had revenue of $0.76 million for the quarter, compared to analysts' expectations of $1.46 million. During the same period last year, the firm posted ($2.00) EPS. Reata Pharmaceuticals's revenue was down 65.7% on a year-over-year basis. Equities research analysts forecast that Reata Pharmaceuticals will post -8.27 EPS for the current year.

Receive RETA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RETA Stock News Headlines

Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next
If you think our current cycle of conflict and chaos started when Russia invaded Ukraine, think again. This cycle actually began over 13 years ago with the most dangerous money-printing escapade of modern times … leading to one of the most sudden surges of inflation in 100 years. This is why Sean Brodrick and Martin Weiss have just held a series of emergency meetings exposing what investors can expect as this crisis unfolds.
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next
If you think our current cycle of conflict and chaos started when Russia invaded Ukraine, think again. This cycle actually began over 13 years ago with the most dangerous money-printing escapade of modern times … leading to one of the most sudden surges of inflation in 100 years. This is why Sean Brodrick and Martin Weiss have just held a series of emergency meetings exposing what investors can expect as this crisis unfolds.
Reata Pharmaceuticals Earnings Preview
Reata Pharmaceuticals (NASDAQ:RETA) Trading 9.9% Higher
Recap: Reata Pharmaceuticals Q4 Earnings
See More Headlines
Receive RETA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RETA Company Calendar

Last Earnings
8/08/2022
Today
8/14/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RETA
Fax
N/A
Employees
346
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$57.57
High Stock Price Forecast
$112.00
Low Stock Price Forecast
$27.00
Forecasted Upside/Downside
+173.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$-297,390,000.00
Net Margins
-3,045.98%
Pretax Margin
-3,043.50%

Debt

Sales & Book Value

Annual Sales
$11.49 million
Book Value
$1.88 per share

Miscellaneous

Free Float
26,022,000
Market Cap
$767.23 million
Optionable
Optionable
Beta
1.09

Key Executives

  • Mr. J. Warren Huff (Age 68)
    Chairman & CEO
    Comp: $642.4k
  • Mr. Manmeet Singh Soni (Age 44)
    COO, CFO & Pres
    Comp: $1.15M
  • Mr. Michael D. Wortley (Age 74)
    Exec. VP & Chief Legal Officer
    Comp: $563.22k
  • Dr. Colin J. Meyer M.D. (Age 43)
    Exec. VP & Chief Innovation Officer
    Comp: $742.5k
  • Ms. Dawn Carter Bir (Age 51)
    Exec. VP & Chief Commercial Officer
    Comp: $569.42k
  • Mr. Bhaskar Anand (Age 45)
    VP & Chief Accounting Officer
  • Dr. W. Christian Wigley Ph.D.
    Sr. VP & Chief Scientific Officer
  • Mr. Dakota Gallivan
    VP & Chief Healthcare Compliance Officer
  • Mr. Steve Harman
    Sr. VP & Chief HR Officer
  • Ms. Elaine Castellanos
    Consultant













RETA Stock - Frequently Asked Questions

Should I buy or sell Reata Pharmaceuticals stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Reata Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RETA shares.
View RETA analyst ratings
or view top-rated stocks.

What is Reata Pharmaceuticals' stock price forecast for 2022?

6 analysts have issued 1-year price targets for Reata Pharmaceuticals' stock. Their RETA share price forecasts range from $27.00 to $112.00. On average, they predict the company's stock price to reach $57.57 in the next twelve months. This suggests a possible upside of 173.9% from the stock's current price.
View analysts price targets for RETA
or view top-rated stocks among Wall Street analysts.

How have RETA shares performed in 2022?

Reata Pharmaceuticals' stock was trading at $26.37 at the beginning of the year. Since then, RETA shares have decreased by 20.3% and is now trading at $21.02.
View the best growth stocks for 2022 here
.

When is Reata Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our RETA earnings forecast
.

How were Reata Pharmaceuticals' earnings last quarter?

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) released its quarterly earnings results on Monday, August, 8th. The company reported ($2.02) EPS for the quarter, missing the consensus estimate of ($1.90) by $0.12. The firm had revenue of $0.76 million for the quarter, compared to the consensus estimate of $1.46 million. Reata Pharmaceuticals had a negative trailing twelve-month return on equity of 190.87% and a negative net margin of 3,045.98%. The company's quarterly revenue was down 65.7% on a year-over-year basis. During the same quarter in the previous year, the business posted ($2.00) earnings per share.

What is Warren Huff's approval rating as Reata Pharmaceuticals' CEO?

10 employees have rated Reata Pharmaceuticals Chief Executive Officer Warren Huff on Glassdoor.com. Warren Huff has an approval rating of 92% among the company's employees. This puts Warren Huff in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Reata Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Reata Pharmaceuticals investors own include Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Synlogic (SYBX), NVIDIA (NVDA), Basic Energy Services (BAS), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO) and Archrock (AROC).

When did Reata Pharmaceuticals IPO?

(RETA) raised $60 million in an initial public offering (IPO) on Thursday, May 26th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray served as the underwriters for the IPO.

What is Reata Pharmaceuticals' stock symbol?

Reata Pharmaceuticals trades on the NASDAQ under the ticker symbol "RETA."

Who are Reata Pharmaceuticals' major shareholders?

Reata Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Franklin Resources Inc. (1.74%), Deutsche Bank AG (1.73%), FMR LLC (1.45%), Emerald Advisers LLC (0.79%), Northern Trust Corp (0.72%) and Emerald Mutual Fund Advisers Trust (0.69%). Insiders that own company stock include Colin John Meyer, Elaine Castellanos, James W Traweek Jr, James Warren Huff, Jason Douglas Wilson and Michael D Wortley.
View institutional ownership trends
.

How do I buy shares of Reata Pharmaceuticals?

Shares of RETA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Reata Pharmaceuticals' stock price today?

One share of RETA stock can currently be purchased for approximately $21.02.

How much money does Reata Pharmaceuticals make?

Reata Pharmaceuticals (NASDAQ:RETA) has a market capitalization of $767.23 million and generates $11.49 million in revenue each year. The company earns $-297,390,000.00 in net income (profit) each year or ($8.37) on an earnings per share basis.

How many employees does Reata Pharmaceuticals have?

The company employs 346 workers across the globe.

How can I contact Reata Pharmaceuticals?

Reata Pharmaceuticals' mailing address is 5320 LEGACY DRIVE, PLANO TX, 75024. The official website for the company is www.reatapharma.com. The company can be reached via phone at (972) 865-2219 or via email at ir@reatapharma.com.

This page (NASDAQ:RETA) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.